Coronavirus testing is becoming increasingly easy even as drugmakers stumble on the development of much-needed vaccines. The Food and Drugs Administration has granted Abbott Laboratories (NYSE:ABT) emergency use approval for a new coronavirus antibody test.
Antibody Testing
AdviseDx is the new coronavirus test on the block that can signal a recent or prior infection of the deadly virus. The antibody test is configured to detect the immunoglobulin antibody in blood samples. It differs from the previous Abbott test that focused on the Iggy antibody.
Abbott has essentially developed systems for detecting the virus at each stage of infection. For instance, the IgM antibody can determine whether someone had COVID-19 infection as it becomes undetectable for several weeks. The IgG antibody, on the other hand, remains detectable in the body or much longer.
Antibody tests are becoming a preferred means for testing coronavirus, given their ability to detect the virus, even where a patient is in a recovery phase. To date, Abbott has developed seven coronavirus tests, all of which have received emergency authorization, including molecular tests and a rapid antigen test.
Coronavirus Vaccine Stalemate
The FDA's emergency authorization is designed to ensure the use of unapproved medical products in emergency situations like the one presented by the COVID-19 pandemic. The authorization is intended to prevent serious or life-threatening diseases that have no approved alternatives.
The success in coronavirus testing is in stark contrast to the development of vaccines. Drugmakers are increasingly struggling to come up with vaccines or treatments that will put the pandemic under control.
Johnson & Johnson (NYSE:JNJ) have already suffered a major blow on developing its coronavirus vaccine. The company has had to halt its phase 3 trials after one of the patients developed an unknown illness. The same fate befell AstraZeneca plc. (NASDAQ:AZN) last month after one of the participants developed a neurological condition.
Stalemate in the development of coronavirus vaccine and treatment has seen the number of infections surge to 37 million worldwide ahead of a challenging winter season. Deaths have already surged to more than 1 million.